Journal
HEART FAILURE CLINICS
Volume 9, Issue 4, Pages 407-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2013.06.001
Keywords
Antiarrhythmic drugs; Atrial fibrillation; Heart failure; Rhythm control
Categories
Funding
- European Network for Translational Research in Atrial Fibrillation (EUTRAF) [261057]
- German Federal Ministry of Education and Research (AF Competence Network) [01Gi0204]
- German Federal Ministry of Education and Research (DZHK [German Center for Cardiovascular Research])
- Deutsche Forschungsgemeinschaft [Do 769/1-3]
- Fondation Leducq (European-North American Atrial Fibrillation Research Alliance, ENAFRA) [07CVD03]
Ask authors/readers for more resources
Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular pathologies with severe prognostic implications that show bidirectional interactions. Rate and rhythm control are the main therapeutic strategies for patients with AF and HF. There is a paucity of safe and effective antiarrhythmic drugs for rhythm control of AF in HF, with amiodarone and (in the United States) dofetilide as the only imperfect options. The basic mechanisms of AF are discussed and the evidence and limitations of AF rhythm control options for patients with HF are reviewed. In addition, novel potential antiarrhythmic strategies for rhythm control of AF are highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
